The popularity of DPC's random-access immunoassay system, the Immulite 2000, has helped the company become a significant player in the highly competitive automated immunoassay market. But DPC's benefited from some good luck--namely the misfortunes of top player Abbott Diagnostics and the slow efforts by other competitors to step into the gap left by Abbott. DPC's dilemma is whether it can maintain its narrow focus as Abbott re-emerges and other competitors get stronger.
By Wendy Diller
Four years ago, Diagnostic Products Corp. was at a turning point. Founder Sigi Ziering, known for his Euro-centric perspective...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
